SCHEMBL19981530

SCHEMBL19981530

COP(C)(=O)N1CCC(N2CCOCC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL3 Q96JM7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.34
KDM4E B2RXH2 4/20 0.34
OPRL1 P41146 2/20 0.33
INSR P06213 1/20 0.33
IGF1R P08069 1/20 0.33
ALK Q9UM73 1/20 0.33
EPHX2 P34913 1/20 0.33
ACHE P22303 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HRH3 Q9Y5N1 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
USP5 P45974 1/20 0.31
CHRM2 P08172 2/20 0.31
CHRM4 P08173 2/20 0.31
CHRM1 P11229 2/20 0.31
CHRM5 P08912 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15443760 0.83 MEN1 (0.41) SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E
SCHEMBL14417614 0.82 GAA (0.38) SMN1; SMN2KDM4EALDH1A1MEN1KMT2A
SCHEMBL15871546 0.81 SMN1; SMN2 (0.34) SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E
SCHEMBL22388964 0.79 MEN1 (0.34) SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E
SCHEMBL19981539 0.73 CHRM2 (0.33) L3MBTL3L3MBTL1CHRM2CHRM1CHRM3
SCHEMBL14995421 0.72 L3MBTL3 (0.42) SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E
SCHEMBL16877830 0.71
SCHEMBL14862483 0.71 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1
SCHEMBL25775999 0.71
SCHEMBL12706415 0.71 SMN1; SMN2 (0.40) SMN1; SMN2L3MBTL3L3MBTL1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788488-B1 METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA SAREPTA THERAPEUTICS INC (US) 2018-03-21 EP disclosed